Trade-off between survival and laryngeal preservation in advanced laryngeal cancer: The otorhinolaryngology patient's perspective

Annals of Otology, Rhinology and Laryngology

Volumn 121, Issue 9, 2012, Pages 570-575

  Laccourreye, Ollivier ^a   Malinvaud, David ^a   Holsinger, F Christopher ^a,b   Consoli, Silla ^a   Ménard, Madeleine ^a   Bonfils, Pierre ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Laryngeal cancer; Organ preservation; Patient's opinion; Trade off

Indexed keywords

ADOLESCENT; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; EDUCATIONAL STATUS; FEMALE; HUMAN; LARYNGECTOMY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; OCCUPATION; ORGAN PRESERVATION; PATIENT ATTITUDE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPEECH;

EID: 84857950347     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348941212100902     Document Type: Article

References (21)

1. Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2007;133:1270-6.
2. McNeil BJ, Weichselbaum R, Pauker SG. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med 1981;305:982-7.
3. Holsinger FC. Swing of the pendulum: optimizing functional outcomes in larynx cancer. Curr Oncol Rep 2008;10:170-5.
4. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-90.
5. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
6. Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx. Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 2006;24(18S):5517.
7. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006;116(suppl 111):1-13.
8. American Society of Clinical Oncology, Pfister DG, Laurie SA, Weinstein GS, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006;24:3693-704.
9. Loi no 2002-203 du 4 mars 2002 relative aux droits des malades et à la qualité du système de santé. J O Rep Fr, 5 mars 2002, 4118-58.
10. Sommers BD, Beard CJ, D'Amico AV, Kaplan I, Richie JP, Zeckhauser RJ. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 2008;113: 2058-67.
11. Zolciak A, Bujko K, Kepka L, Oledzki J, Rutkowski A, Nowacki MP. Abdominoperineal resection or anterior resection for rectal cancer: patient preferences before and after treatment. Colorectal Dis 2006;8:575-80.
12. Hankins J, Hinds P, Day S, et al. Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatr Blood Cancer 2007;48:705-10.
13. Unic I, Verhoef LC, Stalmeier PF, van Daal WA. Prophylactic mastectomy or screening in women suspected to have the BRCA1/2 mutation: a prospective pilot study of women's treatment choices and medical and decision-analytic recommendations. Med Decis Making 2000;20:251-62.
14. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 1997;15:330-40.
15. Brundage MD, Feldman-Stewart D, Cosby R, et al. Cancer patients' attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support. Patient Educ Couns 2001;45:149-57.
16. Cheung SW, Aranda D, Driscoll CL, Parsa AT. Mapping clinical outcome expectations to treatment decision: an application to vestibular schwannoma management. Otol Neurotol 2010;31:284-93.
17. Stiggelbout AM, de Haes JC, Kiebert GM, Kievit J, Leer JW. Tradeoffs between quality and quantity of life: development of the QQ Questionnaire for Cancer Patient Attitudes. Med Decis Making 1996;16:184-92.
18. Solomon MJ, Pager CK, Keshava A, et al. What do patients want? Patient preferences and surrogate decision making in the treatment of colorectal cancer. Dis Colon Rectum 2003;46:1351-7.
19. Bruera E, Willey JS, Palmer JL, Rosales M. Treatment decisions for breast carcinoma: patient preferences and physician perceptions. Cancer 2002;94:2076-80.
20. Basu A, Dale W, Elstein A, Meltzer D. A time tradeoff method for eliciting partner's quality of life due to patients' health states in prostate cancer. Med Decis Making 2010;30:355-65.
21. Jansen SJ, Stiggelbout AM, Wakker PP, et al. Patients' utilities for cancer treatments: a study of the chained procedure for the standard gamble and time tradeoff. Med Decis Making 1998;18:391-9.